BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 23970715)

  • 1. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy.
    Tesfaye S; Boulton AJ; Dickenson AH
    Diabetes Care; 2013 Sep; 36(9):2456-65. PubMed ID: 23970715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on Tesfaye et al. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes care 2013;36:2456-2465.
    Nickerson DS
    Diabetes Care; 2014 May; 37(5):e120. PubMed ID: 24757246
    [No Abstract]   [Full Text] [Related]  

  • 3. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain.
    Tesfaye S; Wilhelm S; Lledo A; Schacht A; Tölle T; Bouhassira D; Cruccu G; Skljarevski V; Freynhagen R
    Pain; 2013 Dec; 154(12):2616-2625. PubMed ID: 23732189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life.
    Boyle J; Eriksson ME; Gribble L; Gouni R; Johnsen S; Coppini DV; Kerr D
    Diabetes Care; 2012 Dec; 35(12):2451-8. PubMed ID: 22991449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
    Tanenberg RJ; Irving GA; Risser RC; Ahl J; Robinson MJ; Skljarevski V; Malcolm SK
    Mayo Clin Proc; 2011 Jul; 86(7):615-26. PubMed ID: 21719618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating diabetic peripheral neuropathic pain.
    Lindsay TJ; Rodgers BC; Savath V; Hettinger K
    Am Fam Physician; 2010 Jul; 82(2):151-8. PubMed ID: 20642268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
    Quilici S; Chancellor J; Löthgren M; Simon D; Said G; Le TK; Garcia-Cebrian A; Monz B
    BMC Neurol; 2009 Feb; 9():6. PubMed ID: 19208243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-utility comparison of four first-line medications in painful diabetic neuropathy.
    O'Connor AB; Noyes K; Holloway RG
    Pharmacoeconomics; 2008; 26(12):1045-64. PubMed ID: 19014205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on therapy: when two are not better than one.
    Finnerup NB
    Pain; 2013 Dec; 154(12):2579-2580. PubMed ID: 23792282
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.
    Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
    Am J Health Syst Pharm; 2013 Dec; 70(24):2207-17. PubMed ID: 24296843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review.
    Ardeleanu V; Toma A; Pafili K; Papanas N; Motofei I; Diaconu CC; Rizzo M; Stoian AP
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936646
    [No Abstract]   [Full Text] [Related]  

  • 12. A new look at painful diabetic neuropathy.
    Sloan G; Shillo P; Selvarajah D; Wu J; Wilkinson ID; Tracey I; Anand P; Tesfaye S
    Diabetes Res Clin Pract; 2018 Oct; 144():177-191. PubMed ID: 30201394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current concepts in the management of diabetic polyneuropathy.
    Ziegler D; Papanas N; Schnell O; Nguyen BDT; Nguyen KT; Kulkantrakorn K; Deerochanawong C
    J Diabetes Investig; 2021 Apr; 12(4):464-475. PubMed ID: 32918837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented Corneal Nerve Fiber Branching in Painful Compared With Painless Diabetic Neuropathy.
    Püttgen S; Bönhof GJ; Strom A; Müssig K; Szendroedi J; Roden M; Ziegler D
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6220-6228. PubMed ID: 31390004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pregabalin and duloxetine for the treatment of neuropathic pain disorders.
    Terneus W
    J Pain Palliat Care Pharmacother; 2007; 21(1):79-84. PubMed ID: 17430838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregabalin: an antiepileptic agent useful for neuropathic pain.
    Blommel ML; Blommel AL
    Am J Health Syst Pharm; 2007 Jul; 64(14):1475-82. PubMed ID: 17617497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy.
    Mittal M; Pasnoor M; Mummaneni RB; Khan S; McVey A; Saperstein D; Herbelin L; Ridings L; Wang Y; Dimachkie MM; Barohn RJ
    Int J Neurosci; 2011 Sep; 121(9):521-7. PubMed ID: 21671841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis.
    Tanenberg RJ; Clemow DB; Giaconia JM; Risser RC
    Pain Pract; 2014 Sep; 14(7):640-8. PubMed ID: 24152185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study.
    Raputova J; Srotova I; Vlckova E; Sommer C; Üçeyler N; Birklein F; Rittner HL; Rebhorn C; Adamova B; Kovalova I; Kralickova Nekvapilova E; Forer L; Belobradkova J; Olsovsky J; Weber P; Dusek L; Jarkovsky J; Bednarik J
    Pain; 2017 Dec; 158(12):2340-2353. PubMed ID: 28858986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Painful neuropathies.
    Sommer C
    Curr Opin Neurol; 2003 Oct; 16(5):623-8. PubMed ID: 14501847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.